Japan Lifeline Co.,Ltd. Q4 FY2025 earnings call

• Overall Financial Performance
  • Nihon Lifeline achieved double-digit growth in both revenue and profit for FY2025/3, with all key metrics hitting all-time highs: total revenue of 56.61 billion yen (+10.2% YoY), operating profit of 12.326 billion yen (+13.2% YoY), and net income of 9.317 billion yen (+24% YoY). The large net income growth includes a one-off 351 million yen deferred tax asset recorded in Q4 from a previously impaired unlisted stake becoming publicly tradable.
  • Operating profit grew 1.434 billion yen YoY: 3.203 billion yen in growth from sales/cost factors offset a 1.769 billion yen decline from higher SG&A. Growth drivers included core product volume increases, new area volume growth, and no repeat of prior year inventory valuation losses; SG&A increases came from PFA R&D, higher salaries, expanded sales activities, SAP depreciation, and a one-off bad debt provision from a supplier bankruptcy.
  • Overseas sales share grew 0.5pp YoY, while proprietary product share fell 1.4pp due to expanded procurement of cerebrovascular and hemostasis devices. EPS grew 33.1% YoY to 131.43 yen due to share buybacks.
• Mid-Term Management Plan (FY2024/3 to FY2028/3) Progress & Update
  • Original 2025/3 sales targets have been exceeded by 5.6 billion yen (actual 56.6 billion yen vs original plan 51 billion yen), putting the plan ~1 year ahead of schedule; operating profit, EPS, and ROIC also all beat original targets, with ROIC reaching 13.7% vs the 12% target.
  • Cerebrovascular full lineup completion is 20% ahead of plan; gastroenterology is slightly behind plan but on track to hit full 5-year targets. Core products BeeAT and FET maintain over 90% market share despite expected competitor entry.
  • Management has upwardly revised the full mid-term plan targets: final year (FY2028/3) total sales raised from 630 billion yen to 700 billion yen; new area sales raised from 80 billion yen to 110 billion yen; final year EPS raised from 120 yen to 145 yen; ROIC target raised 1pp to 13%.
• New Growth Strategies
  • Entry into the structural heart disease space: planning to launch transcatheter biological valve TAVI in FY2027/3 (a 100+ billion yen domestic market with only one current competitor offering balloon-expandable devices), plus add patent foramen ovale (PFO) closure devices to the existing atrial septal defect closure device portfolio.
  • Joint development of PFA products with CardioFocus: First-in-human and Second-in-human trials are already completed in Europe. The company manufactures the catheters for the program, with full catheter development responsibility for next-generation products. PFA is a large market (600-800 billion yen domestic, $70-120 billion global), with domestic launch planned for FY2029/3 and overseas OEM shipments starting in FY2028/3.
  • Global sales expansion: Currently focused on penetration in Asia and the Middle East using Japanese approval, with QMS system upgrades underway to support future entry into Europe and North America. The medium-long term target is to raise overseas sales share to 30%, with 20-30 billion yen in global sales targeted for FY2028/3.
• Financial & Capital Strategy
  • Expected cumulative operating cash flow of ~300 billion yen over the next 3 years: 60 billion yen for facility maintenance/updates, 140-200 billion yen for growth investment (PFA clinical development, R&D, expanded manufacturing capacity for global expansion). Excess cash will be allocated to shareholder returns.
  • Total shareholder return target for the mid-term period is raised from 250 billion yen to 270-300 billion yen, with 154 billion yen already returned. 4.458 million excess treasury shares will be canceled in May.
  • Dividend for FY2026/3 is planned at 54 yen per share, in line with the company's policy of 40% payout or 5% DOE, whichever is higher.

For FY2025/3 (full year ended March 2025):

1. Rhythm Devices: Total revenue decreased 1.7% YoY to 134.67 billion yen (after conversion). S-ICD grew 12.4% YoY from new case acquisitions, while pacemaker-related revenue fell ~14% YoY due to official price revisions and competitor leadless pacemaker market penetration.
2. EP/Ablation: Total revenue increased 14.8% YoY to 278.45 billion yen, contributing 68.8% of total FY2025/3 revenue growth. Core intracardiac defibrillation catheters grew 8.7% YoY on 10% YoY atrial fibrillation (AF) case growth, and new hemostasis devices grew 4.7% YoY from expanded facility adoption, partially offset by a 1.2% decline in esophageal temperature monitoring catheters due to accelerating PFA adoption.
3. Cardiovascular Related: Total revenue increased 7.0% YoY to 121.99 billion yen. Core Frozen Elephant Trunk (FET) grew 9.6% YoY from procedure adoption and market expansion, while abdominal stent grafts grew 5.3% YoY.
4. Cerebrovascular Related: Total revenue doubled YoY to 18.59 billion yen, with 929 million yen in net revenue growth. Embolization coils grew 1.6x YoY after new model launches; stent retrievers launched in Q2 drove strong sales growth, and created synergies with the existing thrombus aspiration catheter, which grew 2.3x YoY.
5. Gastroenterology: Excluding discontinued businesses, revenue grew 45.3% YoY to 131.9 million yen, driven by new product launches centered on the core biliary tube stent, bulk inventory sales from outsourcing of liver cancer ablation products to Terumo, and improved versions of gastro-duodenal stents.

• FY2026/3 (full year ending March 2026) guidance calls for total revenue of 593 billion yen (+4.8% YoY), operating profit of 129 billion yen (+4.7% YoY), and net income of 9.35 billion yen (+0.3% YoY, with low growth due to the absence of the FY2025/3 one-off deferred tax asset). All metrics will hit new all-time highs if achieved.
• Segment-level revenue guidance: Rhythm Devices expects a 0.3% YoY revenue decline (pacemaker to fall 8% YoY on expanding competitor leadless market share, S-ICD to fall 3-4% YoY due to lower replacement cases, partially offset by the new May 2025 launch of lead management products acquired from Philips in a ~7 billion yen total market). EP/Ablation expects +4.7% YoY growth to 291.44 billion yen, driven by 8-9% growth in intracardiac defibrillation catheters (on 10% YoY AF case growth, maintaining 95% market share) and ~20% growth in hemostasis devices, partially offset by a 30% decline in esophageal temperature monitoring catheters from 40-50% PFA market penetration and the end of RF Needle sales support in December 2025 cutting 3 months of revenue. Cardiovascular Related expects +3.6% YoY growth to 126.42 billion yen, with 8-9% growth for FET (maintaining >90% share), ~10% growth for atrial septal defect closure devices from relaxed facility certification requirements, and flat abdominal stent grafts. Cerebrovascular Related expects +22.7% YoY growth to 22.7 billion yen, with 10% growth for embolization coils from expanded cross-specialty use, ~30% growth for thrombus aspiration catheters from synergies with stent retrievers, and 2x YoY growth for stent retrievers from an upcoming improved model launch. Gastroenterology (exiting discontinued business) expects +40.9% YoY growth to 186.9 million yen, driven by 25-30% growth in biliary tube stents from two new model launches after refocusing sales resources on the core biliary-pancreatic segment.
• Gross margin is expected to fall 0.7pp YoY due to the end of the RF Needle sales support agreement and production adjustments, but operating margin is expected to remain flat YoY as sales growth offsets higher SG&A from salary increases and ongoing PFA R&D.

• Pricing pressure from official medical price revisions reduced average selling prices and created a 748 million yen operating profit headwind in FY2025/3, and continues to pressure margin for price-sensitive segments like pacemakers.
• Competitor product expansion: Competitor leadless pacemakers are gaining market share, pressuring traditional pacemaker sales, and competitor development of new conduction system pacing leadless devices targeting the His bundle could create long-term competitive pressure if the technology gains clinical traction.
• PFA adoption is progressing faster than originally expected, which is accelerating the decline of existing products like esophageal temperature monitoring catheters that are replaced by PFA workflows.
• Abdominal stent grafts face a mature, flat market and the company has already captured most eligible cases for its current product lineup, limiting future growth potential.
• Entry into the large European and North American markets faces heightened regulatory hurdles (EU MDR, FDA QMSR requirements) that increase compliance costs and expansion timelines.

Q: Why is cardiovascular segment overall growth only 3.6% YoY when all core sub-segments are projected to grow at nearly 10%? What factors are holding back growth, and is there upside potential for FET growth? / A: The low overall growth rate is driven by abdominal stent grafts, which make up ~4 billion yen (nearly 40%) of the cardiovascular segment revenue. The abdominal stent graft market has been flat for several years, and the company has already captured most eligible cases for its current two-product lineup, so revenue is expected to be nearly flat. While FET could see moderate upside from seasonal increases in acute A-type dissection cases during periods of large temperature swings, large upside surprises are not expected.

Q: What is Boston Scientific's Denali Program, and what is the competitive threat from Abbott's new leadless conduction system pacing device that directly implants into the His bundle? / A: The Denali Program is Boston Scientific's codename for a full platform refresh of its entire pacemaker and ICD portfolio, focused on adding missing competitive features and making minor size/shape adjustments. Conduction system pacing targeting lower conduction pathways is already becoming an industry trend, and Nihon Lifeline is aware of competitor development. While a fully leadless His bundle pacing device would be a meaningful competitive threat if successfully commercialized, Nihon Lifeline management questions whether the technology is ready for widespread adoption today, as His bundle pacing is already a very technically challenging procedure with existing leads.

Q: Can you share details on OEM opportunities leveraging the company's catheter technology, and is M&A being considered to lower the barrier to entry for Western markets? / A: The company has received inbound OEM interest for its proprietary catheter technology, and potential opportunities are being discussed, though no specific details can be shared at this stage. For global expansion, the company is already prioritizing building Western regulatory-compliant quality systems to meet EU MDR and FDA requirements. M&A is not currently actively pursued, but any deal that creates clear synergies (domestic or international) will be considered, and there are already preliminary opportunities under evaluation.

Q: Why is PFA penetration projected to reach only 40-50% by FY2026/3 end, after faster-than-expected adoption in late FY2025/3? How will this affect the company's existing product portfolio? / A: Adoption has indeed been faster than expected: 70-80% of high-volume hospitals (with 200+ annual cases) have already adopted PFA. Future growth will slow as adoption shifts to lower-volume hospitals, where PFA is less cost-justified, so the 40-50% penetration projection is conservative. While PFA adoption will reduce revenue from esophageal temperature monitoring catheters, overall AF case count growth will offset this decline, and the company's core BeeAT intracardiac defibrillation catheter will remain a standard part of PFA workflows, so the net impact is manageable.